Cerus Co. (NASDAQ:CERS) has received an average rating of “Hold” from the six ratings firms that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and three have issued a buy recommendation on the company. The average 12 month target price among brokerages that have covered the stock in the last year is $9.50.
Several brokerages have issued reports on CERS. BidaskClub downgraded Cerus from a “hold” rating to a “sell” rating in a report on Friday. ValuEngine downgraded Cerus from a “strong-buy” rating to a “buy” rating in a report on Friday, March 22nd. Finally, Zacks Investment Research downgraded Cerus from a “buy” rating to a “hold” rating in a report on Monday, March 4th.
In other news, CEO William Mariner Greenman sold 7,781 shares of the company’s stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $6.48, for a total transaction of $50,420.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Carol Moore sold 10,886 shares of the company’s stock in a transaction dated Wednesday, March 13th. The stock was sold at an average price of $6.01, for a total value of $65,424.86. The disclosure for this sale can be found here. Insiders have sold 57,650 shares of company stock valued at $257,460 over the last ninety days. 6.80% of the stock is owned by insiders.
NASDAQ CERS traded down $0.05 on Monday, reaching $5.75. The company had a trading volume of 447,211 shares, compared to its average volume of 698,591. The company has a market capitalization of $787.48 million, a PE ratio of -13.07 and a beta of 1.42. The company has a current ratio of 2.79, a quick ratio of 2.53 and a debt-to-equity ratio of 0.26. Cerus has a 52 week low of $4.70 and a 52 week high of $8.05.
Cerus (NASDAQ:CERS) last announced its quarterly earnings results on Tuesday, February 26th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.02). Cerus had a negative return on equity of 65.35% and a negative net margin of 84.15%. The business had revenue of $16.50 million during the quarter, compared to the consensus estimate of $18.74 million. During the same quarter last year, the company earned ($0.10) earnings per share. The firm’s revenue was up 1.9% compared to the same quarter last year. As a group, sell-side analysts predict that Cerus will post -0.42 earnings per share for the current fiscal year.
Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
See Also: What is a Leveraged Buyout (LBO)?
Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.